Physician and Stakeholder Perceptions of Conflict of Interest Policies in Oncology.

Lockhart AC, Brose MS, Kim ES, Johnson DH, Peppercorn JM, Michels DL, Storm CD, Schuchter LM, Rathmell WK.

Source

A. Craig Lockhart, Washington University Siteman Cancer Center, St Louis, MO; Marcia S. Brose and Lynn M. Schuchter, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte; Jeffrey M. Peppercorn, Duke University Medical Center, Durham; W. Kimryn Rathmell, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; David H. Johnson, University of Texas Southwestern Medical School, Dallas, TX; and Dina L. Michels and Courtney D. Storm, American Society of Clinical Oncology, Alexandria, VA.

Abstract

PURPOSE The landscape of managing potential conflicts of interest (COIs) has evolved substantially across many disciplines in recent years, but rarely are the issues more intertwined with financial and ethical implications than in the health care setting. Cancer care is a highly technologic arena, with numerous physician-industry interactions. The American Society of Clinical Oncology (ASCO) recognizes the role of a professional organization to facilitate management of these interactions and the need for periodic review of its COI policy (Policy).

METHODS To gauge the sentiments of ASCO members and nonphysician stakeholders, two surveys were performed. The first asked ASCO members to estimate opinions of the Policy as it relates to presentation of industry-sponsored research. Respondents were classified as consumers or producers of research material based on demographic responses. A similar survey solicited opinions of nonphysician stakeholders, including patients with cancer, survivors, family members, and advocates.

Results The ASCO survey was responded to by 1,967 members (1% of those solicited); 80% were producers, and 20% were consumers. Most respondents (93% of producers; 66% of consumers) reported familiarity with the Policy. Only a small proportion regularly evaluated COIs for presented research. Members favored increased transparency about relationships over restrictions on presentations of research. Stakeholders (n = 264) indicated that disclosure was "very important" to "extremely important" and preferred written disclosure (77%) over other methods.

CONCLUSION COI policies are an important and relevant topic among physicians and patient advocates. Methods to simplify the disclosure process, improve transparency, and facilitate responsiveness are critical for COI management.

TimAllenMDJD

Wednesday, March 27, 2013